Financials

Financials — Reading a $45 Billion Medicaid Insurer at a Margin Trough

Molina is a thin-margin, government-funded health insurer: it collects fixed monthly premiums from state Medicaid agencies, the federal Medicare program, and the ACA Marketplaces, then pays members' medical claims out of that premium. The single number that decides whether Molina makes money is the Medical Care Ratio (MCR) — medical claims as a percentage of premium revenue (the managed-care equivalent of an insurer's loss ratio; lower is better). On a ~1–4% net margin, a couple of points of MCR is the difference between a good year and a bad one — and FY2025 was a bad one. Revenue grew 12% to a record $45.4 billion, yet net income fell 60% and diluted EPS collapsed from $20.42 to $8.92 [1]. This page is about why, how fragile or durable the franchise is underneath, and what the market is paying for the recovery.

The 30-Second Read

Sources: FY2025 10-K, Financial Results Summary [2]; MCR detail [3].

Source: MCR sensitivity disclosure, FY2025 10-K Risk Factors [4].

The seasoned read: this is a margin-recovery trade, not a growth story. Molina served approximately 5.5 million members across 21 states at year-end 2025, and revenue has nearly tripled since 2019 [5]. But the stock — recently around $216 — discounts almost none of the trough earnings and everything about a normalization that management guides to "at least $5" of adjusted EPS in 2026 (down from a pre-crisis run-rate above $22), before a hoped-for climb back toward double-digit earnings power [6]. Whether the MCR returns to its ~88% long-term zone is the entire debate.

How Molina Actually Earns: Premium In, Claims Out

Molina has no "gross margin" in the conventional sense. Its income statement is a spread between premium revenue and the medical costs it pays on behalf of members, captured as medical margin (premium revenue minus medical care costs). In FY2025 premium revenue was $43.1 billion and medical costs were $39.5 billion, leaving medical margin of $3.56 billion — down from $4.20 billion in 2024 despite $4.4 billion (11%) more premium [7]. After a 6.6% G and A ratio, operating income was just $781 million — a 1.7% operating margin [8]. That is the structural reality: on every premium dollar, ~92 cents goes to claims and ~6.6 cents to overhead, leaving pennies of pre-tax profit. Scale and cost discipline matter, but the medical cost trend dominates everything.

Revenue is heavily concentrated in Medicaid, with Medicare and Marketplace as smaller, higher-volatility books.

Source: segment premium revenue, FY2025 10-K Reportable Segments [9]; prior-year segment figures as reported in respective 10-Ks.

Medicaid is roughly three-quarters of premium — a book whose rates are set by states in advance and re-priced on a lag. That lag is the franchise's core vulnerability: when members' health acuity or utilization rises faster than the actuarial assumptions baked into the next rate cycle, Molina eats the gap until rates catch up. Marketplace (ACA exchange) is the smallest but most volatile segment — its MCR has historically swung from the high-50s to the low-90s as membership and pricing shift.

The Standard Year-Wise Statements

Source: derived from reported financials, FY2016–FY2025 10-Ks; FY2025 figures per the FY2025 10-K [10]. MCR is the consolidated medical care ratio; ROE is net income over year-end equity.

Read top to bottom, the table tells the franchise's two-act story. Act one (2018–2024): a clean compounder. After the disastrous 2017 (a $512 million loss when the prior management's Marketplace book and operations blew up), a new team cut the MCR to the mid-80s, tripled revenue through Medicaid expansion and acquisitions, and lifted EPS from a loss to $20.42 — all while shrinking the share count. Act two (2025): the trough. MCR jumped to 91.7%, operating margin halved to 1.7%, EPS more than halved, and operating cash flow turned negative. The balance sheet (equity, debt, cash) barely moved — this is an earnings shock, not a solvency event.

The Crux: The Medical Care Ratio Crisis

Everything that went wrong in 2025 routes through the MCR, and it deteriorated in every segment at once — the signature of an industry-wide cost shock rather than a Molina-specific stumble.

Source: segment and consolidated MCR, FY2025 10-K Reportable Segments [11]; prior years per respective 10-Ks.

Management attributes the 260bp consolidated jump to "a challenging medical cost trend environment due to increased utilization that was higher than we expected and acuity shifts in our membership" [12]. Two forces compounded: (1) post-pandemic Medicaid redeterminations purged healthier, lower-cost members from the rolls, leaving a sicker, costlier residual pool that state rates had not yet caught up to (an "acuity shift"); and (2) a broad spike in care utilization. On the Q1 2026 call, management quantified the 2025 medical cost trend at 7.5%, including 250 basis points of acuity shift tied to redeterminations — and said it now assumes that acuity pressure does not recur, budgeting a more normal 5% trend for 2026 [13].

The quarterly path makes the damage visceral — and shows it accelerated into a year-end loss.

Source: quarterly diluted EPS as reported; Q1 FY2026 adjusted EPS of $2.35 per the Q1 FY2026 call [14].

EPS fell sequentially every quarter of 2025 — $5.45, $4.75, $1.51 — and tipped into a $3.15 per-share loss in Q4 as the year's full cost trend was recognized. Q1 2026 GAAP EPS of $0.27 looks like stabilization, and on an adjusted basis Molina reported $2.35 with a 91.1% consolidated MCR — modestly better and "solid under the circumstances," in management's words [15]. The bull case rests on the first-quarter Medicaid trend coming in "modestly favorable" and the acuity shift "behind us"; the bear case is that one quarter is not a trend, and rates may still chase costs for several more cycles.

This is not a Molina-only problem. The same cost wave broke across the entire managed-care group in 2025 — and the two most government-concentrated players took the worst of it.

Source: peer FY2025 Annual Reports (Form 10-K), as reported; Centene's $6.67B net loss per its FY2025 10-K [16].

Centene — Molina's closest peer and the only other pure government-program player — swung to a $6.7 billion net loss in 2025 [17]. The diversified players that blend commercial, pharmacy, and provider businesses — Elevance, UnitedHealth, Cigna — held net margins near 2–3%. The lesson for underwriting Molina: its 100% government-program model gives it the highest exposure to the Medicaid/Marketplace rate-setting cycle and the thinnest cushion when costs run hot. That concentration is the source of both its trough severity and, if rates re-rate upward, its recovery torque.

Earnings Quality: Where the Cash Went

For most companies, cash conversion is a quality check; for an insurer it is also a timing puzzle. Molina collects premiums (capitation) monthly in advance of paying claims, so operating cash flow is normally well above net income — but it swings violently with the timing of government receivable and payable settlements.

Source: Consolidated Statements of Cash Flows and MD and A Liquidity, FY2025 10-K [18]; prior years as reported.

FY2025 operating cash flow was negative $535 million, versus $644 million of cash provided in 2024 — a $1.18 billion swing, and free cash flow of negative $636 million. Capex is trivial for this asset-light model (~$100 million, 0.2% of revenue), so free cash flow tracks operating cash flow almost exactly. Management attributes the swing to "a decline in operating income, timing differences in settlement of government agency receivables and payables — including settlements for Medicaid minimum MLR and medical cost corridors and Marketplace risk adjustment payables — and the timing of tax payments" [19].

The honest read is that the negative cash flow is part real, part timing. The earnings decline is real and was always going to drag cash. But a meaningful chunk is the give-back of prior-period favorable timing (minimum-MLR and corridor settlements where Molina returns excess margin to states, and risk-adjustment payables). That it is partly timing is confirmed by Q1 2026, when operating cash flow rebounded to $1.1 billion on the timing of Medicaid and Marketplace government payments [20]. Over a multi-year window, Molina has converted earnings to cash well (note the $2.0–2.1 billion OCF years of 2020–2021). The 2025 cash drain is a flag to watch, not yet a quality indictment.

The reserve you have to trust

Because Molina pays claims months after care is delivered, the largest judgment on its balance sheet is the incurred-but-not-paid (IBNP) claims reserve — an actuarial estimate of bills not yet received. At year-end 2025, IBNP was $3.21 billion of the $4.89 billion total medical claims-and-benefits-payable liability, and Molina's auditor flagged it as a critical audit matter [21]. Days in claims payable stood at a thin 44 at the end of Q1 2026, which management called "modestly lower than typical" due to payment timing [22]. The investor takeaway: in a rising-cost environment, conservative reserving matters enormously — under-reserving would mean today's reported EPS is borrowed from tomorrow. So far the reserve has held without material adverse development, but it is the line where a cost-trend surprise would show up first.

Balance Sheet: Resilient Holding-Company, Thin Parent Liquidity

On a consolidated basis Molina looks lightly levered: $3.77 billion of total debt against $8.3 billion of cash and investments, i.e. a net cash position, with working capital of $5.1 billion at year-end 2025 [23]. The debt is termed-out with no maturities until 2028 and a laddered profile thereafter.

Source: Note 11, Debt, FY2025 10-K [24].

Two caveats keep this from being a pure fortress balance sheet. First, the credit profile is sub-investment-grade: the senior notes are rated BB by Standard and Poor's and Ba2 by Moody's, and recent issuance has come at much higher coupons — the November 2025 notes priced at 6.500%, versus the 3.875% notes issued in 2021 — so refinancing the ladder will lift the interest bill, which already rose to $192 million in 2025 from $118 million [25], reflecting the higher recent coupons [26]. On a trailing-EBITDA basis leverage is meaningfully higher than the consolidated optics suggest — management cited debt at 6.1x trailing-twelve-month EBITDA and a debt-to-cap ratio of about 48% at the end of Q1 2026, both elevated by the depressed earnings denominator [27]. That ratio mechanically improves as earnings recover; it is a symptom of the trough, not new borrowing.

Second — and more important — most of the cash is trapped. Molina is a holding company; nearly all of that $8.3 billion sits in regulated insurance subsidiaries and can only move up to the parent as state-approved dividends. As of year-end 2025, subsidiaries could pay only ~$170 million in aggregate without prior regulatory approval, and management expects that capacity to decline in 2026 because of the lower 2025 net income [28]. Parent-company cash was only about $213 million at the end of Q1 2026 [29]. So the "net cash" headline overstates real financial flexibility: the parent funds buybacks, acquisitions, and debt service from a modest dividend stream that thins precisely when earnings fall.

Returns and Capital Allocation: Compounding Per-Share, With One Misfire

Molina pays no dividend and reinvests through two channels: tuck-in acquisitions and buybacks. The reinvestment record on returns is genuinely strong outside the trough — ROE ran 25–32% from 2020 through 2024 before the 2025 collapse to 11.6%, and the diluted share count has been ground down from ~66 million (2018) to 52.9 million (2025).

Source: Statements of Cash Flows / Note 13 Stockholders’ Equity, FY2025 10-K [30].

But 2025 contains a real capital-allocation misfire worth naming. Molina spent $1.0 billion on buybacks in 2025 — including roughly 1.68 million shares for $500 million at an average $297.83 in Q1, then 2.85 million shares for $500 million at $175.50 in Q3 [31]. The first tranche was bought near the highs, just before the margin crisis cut the share price roughly in half — a $500 million reminder that even a disciplined repurchaser can mistime its own stock when its earnings are about to break. The April 2025 board authorization of a fresh $1 billion program runs through year-end 2026, so the firepower remains [32]. On the acquisition side, Molina funded the ConnectiCare acquisition (~$245 million net) in Q1 2025, following Bright and MyChoice Wisconsin in 2024 — bolt-ons that feed the "embedded earnings" pipeline management points to as a future profit driver [33].

Valuation: Paying Up for a Recovery That Isn't Guaranteed

Nothing about Molina is "cheap" or "expensive" in the abstract — it is cheap on normalized earnings and expensive on trough earnings, and which lens is right is the whole question.

Source: share price and consensus per market data as of late June 2026; FY2025 EPS of $8.92 per the FY2025 10-K [34]; FY2026 adjusted EPS guidance of at least $5 per the Q1 FY2026 call [35].

At ~$216, Molina trades at about 24x trailing depressed EPS ($8.92), ~42x the FY2026 consensus of ~$5.15, but only roughly 9–10x its pre-crisis earnings power of $20-plus. The market is explicitly not valuing the trough — a 24x trailing or 42x forward multiple would be absurd for a 1% net-margin insurer if these were normal earnings. Instead, investors are paying ~$216 for the right to a normalization back toward an ~88% MCR and high-teens-to-twenties EPS. Three reference points temper that optimism:

• Book value: equity is $4.07 billion, or ~$77 per share, so the stock trades at ~2.8x book — a premium that only makes sense if ROE re-rates back toward its historical 25%+ from today's 11.6%.
• The Street is below the stock: the mean analyst price target is ~$192, under the ~$216 quote, implying analysts on average see modest downside even after the recent contract-win-driven bounce. Targets range widely ($129–$262), reflecting genuine disagreement on the MCR path.
• Guidance is a trough, not a recovery: management guides 2026 to ~$42 billion of premium revenue (a decline, as it deliberately shrinks volatile Marketplace exposure) and "at least $5" of adjusted EPS [36]. The earnings recovery is a 2027-plus story, leaning on rate catch-up and the "embedded earnings" from new contract wins and acquisitions that management frames as a multi-year value driver [37].

Note: This run did not include a third-party Quality Score or Fair Value estimate, so valuation here is anchored to the company's own history, peer margins, consensus EPS, and book value rather than an external scoring model.

What the Financials Confirm, and What They Contradict

Confirmed: Molina is a high-quality operator of a structurally low-margin business — disciplined G and A (6.6%), asset-light, a long record of per-share compounding and 25%+ ROE in normal years, and a balance sheet with no near-term debt cliff. The 2025 collapse is an earnings event driven by a sector-wide medical-cost spike, not a balance-sheet or franchise failure; Molina is no worse off than Centene and arguably navigated 2025 better.

Contradicted: the idea that this is a steady compounder you can underwrite on a clean multiple. The 2025 numbers expose how little margin of safety the model carries — one bad cost year erases 60% of earnings and turns cash flow negative — and how the "net cash" balance sheet overstates parent-level flexibility once you account for trapped regulated capital and a shrinking dividend-up stream. The Q1 2026 buyback timing is a reminder that even good capital allocators get whipsawed when earnings are this gearing-sensitive.

The investment case is therefore binary and almost entirely about one variable: does the medical care ratio mean-revert toward ~88%, restoring high-teens EPS, or does Medicaid rate-setting keep lagging cost trend, leaving Molina earning a fraction of its claimed power while the stock prices in a recovery? Everything else — growth, leverage, cash conversion — is downstream of that ratio.

The first financial metric to watch is the consolidated Medical Care Ratio (and, within it, the Medicaid MCR). At ~92%, every point of improvement back toward management's ~88% long-term zone is worth roughly $6 of EPS, and the Q1 2026 print of 91.1% is the first tentative evidence the acuity shock is fading. If the MCR keeps grinding lower through 2026 with state rate updates catching up to cost trend, the trough-earnings valuation becomes the bargain it pretends to be; if it sticks above 91%, the stock is paying ~42x for earnings that aren't coming back on schedule.